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Abstract
CHARGE is a well-characterized syndrome
(OMIM 2148400) associated with multiple con-
genital anomalies including cardiovascular
malformations. Mutations in CHD7 are the
most common cause of CHARGE syndrome.
Persistent left superior vena cava (LSVC) has
been described in patients with CHARGE syn-
drome in one study of LSVC associations. A ret-
rospective chart review was conducted for all
patients with CHARGE syndrome, diagnosed by
Blake criterion features and/or the presence of
a pathogenic CHD7 mutation. Echocardio -
grams were performed on a clinical basis for
all patients and were systematically reviewed
and classified. Persistent LSVC was present in
50% of patients with CHARGE syndrome (4/8)
and was seen in 3 out of 33 patients seen by
cardiovascular genetics with 22q11.2 deletion
syndrome. Persistent LSVC is a common find-
ing in patients with CHARGE syndrome and its
presence may increase the index of suspicion
in patients with other characteristic congeni-
tal anomalies.
Introduction
CHARGE syndrome (OMIM 2148400) is an
autosomal dominant, multiple congenital
anomaly syndrome. Typically, the occurrence is
sporadic with rare familial cases. The term
CHARGE itself is an acronym of common fea-
tures in this syndrome, including ocular
Coloboma, Heart defects, choanal Atresia,
Retardation of growth and development,
Genitourinary and Ear anomalies including
deafness. The prevalence of CHARGE syn-
drome is estimated to be one in 8500-10,000
live births.1 Cardiovascular malformations
(CVMs) that are typically associated with this
syndrome include conotruncal malformations
[tetralogy of Fallot, double outlet right ventri-
cle, D-transposition of the great arteries
(TGA)], septal defects (atrial septal defects,
ventriculoseptal defects), right ventricular out-
flow tract obstruction (RVOTO, e.g., pulmonary
valve stenosis), and patent ductus arteriosus.2
CHARGE syndrome was formerly a clinical
diagnosis based on particular major and minor
findings. The schema most generally used was
proposed by Blake et al.,3 and there is an addi-
tional clinical criterion schema proposed by
Verloes et al. (Table 1).4 Both systems utilize
similar criteria: endocrine abnormalities
(delayed pubertal development, gonadotropin
or growth hormone deficiency), developmental
delay or intellectual disability, and cranial
nerve dysfunction, in addition to CVM.
Since 2004, the clinical diagnosis of
CHARGE syndrome has been supported by
sequencing of CHD7,5 Chromodomain Helicase
DNA-binding protein active in the developing
embryo. Among patients with a clinical diagno-
sis of CHARGE syndrome by Blake and/or
Verloes criteria, over 90% have pathogenic
mutations, deletions, or duplications of CHD7.6
Patients with truncating mutations of CHD7
are more likely to both meet clinical criteria
(Blake and/or Verloes), have CVMs, choanal
atresia, and cleft lip/palate than patients with
missense mutations of CHD7.7 
There is difficulty in making a clinical diag-
nosis of CHARGE syndrome in the cardiac
intensive care unit (CICU) because newborns
may not have observable threshold criterion
features. Unifying diagnoses impact manage-
ment and therefore timely diagnoses impact
care. Additional congenital anomalies or spe-
cific CVMs that increase suspicion for
CHARGE syndrome would be helpful in the
assessment of newborns in the CICU.
The presence of left superior vena cava
(LSVC) is common in the general population
(0.1-1.7%)8 and may be an asymptomatic con-
genital anomaly discovered in the course of
evaluation for other conditions. LSVC is more
commonly seen in individuals with concurrent
CVMs (10%).8,9 In particular, SVC abnormali-
ties are common in individuals with hetero-
taxy syndromes,10 who may have a LSVC with
or without a persistent right superior vena
cava (bilateral SVC with or without a commu-
nicating vein). There is a high prevalence of
extracardiac findings in patients with LSVC
(51%), and of these, 21% may have heterotaxy
syndrome.8
Previously, Postema and colleagues reported
a case series of 102 consecutive patients with
LSVC in which five patients (5%) with
CHARGE syndrome were identified.11 In addi-
tion, unspecified SVC anomalies were reported
in 5 patients (8%) with CHARGE in an epi-
demiologic survey.1 Larger studies examining
cardiac features in CHARGE syndrome have
not routinely documented SVC findings,2,12-14
thus the true frequency of LSVC in patients
with CHARGE syndrome is unknown.
We reviewed patients with CHARGE syn-
drome seen by the cardiovascular genetics
service at CCHMC to determine the frequency
of venous anomalies. We hypothesized that
there is an increased frequency of LSVC in
patients with a diagnosis of CHARGE syn-
drome. 
Materials and Methods
A retrospective case series of consecutive
patients with a clinical and/or molecular diag-
nosis of CHARGE syndrome and 22q11.2 dele-
tion syndrome followed by the cardiovascular
genetics service at CCHMC from 7/2010-
12/2012 was completed with Institutional
Review Board approval. Blake criteria were
ascertained and typical CHARGE was used as
the standard for clinical diagnosis. We also
evaluated for Verloes criteria in all patients as
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these are weighted differently (Table 1).
Pathogenic mutations of CHD7 were the stan-
dard for laboratory-confirmed diagnosis. All
initial echocardiograms were reviewed by a
cardiologist, and CVMs were classified using
an established taxonomy that identifies both
specific lesions and groups of related lesions.15
As a comparison cohort, patients with 22q11.2
deletion syndrome, a condition with similar
phenotype,16 were evaluated similarly.
Results
Eight patients were ascertained with
CHARGE syndrome (4 female, 7 Caucasian
non-Hispanic, 1 African American). There was
an equal distribution of gender and median
age at diagnosis of approximately 3 months
(0.26 years), however two subjects were ascer-
tained much later at 1.73 years and 12.30 years
in a cardiac neurodevelopmental clinic (Table
2). The 22q11.2 deletion syndrome comparison
group had 33 patients with demographics sim-
ilar to the CHARGE cohort (18 female, 30
Caucasian with one Hispanic, 2 African
American, 1 Asian). All patients with 22q11
Deletion syndrome had typical deletions by flu-
orescent in situ hybridization (FISH) or
microarray studies, were consecutively ascer-
tained during the same time period, and were
also followed by the cardiovascular genetics
service. 
In the CHARGE cohort, the CVM group was
predominantly conotruncal and included septal
defects and RVOTOs (Table 3). Four patients
with CHARGE (4/8; 50%) had persistent LSVC
(bilateral SVC), three patients with LSVC had
TGA with additional cardiac defects.
Interestingly, 5/8 patients (1-5, Table 2),
including all four with LSVC, had cardiac find-
ings consistent with a laterality disorder, a
classification that encompasses heterotaxy
syndromes. In contrast, three of the 22q11.2
deletion syndrome cohort had LSVC (9%). The
22q11 deletion syndrome cohort had the fol-
lowing CVM groups: 22 conotruncal, 6 septal, 1
RVOTO, 4 other [abberrant subclavian artery
(3), and vascular ring (1)].
Patient 1 did not meet Blake criteria, but did
meet Verloes criteria as atypical CHARGE
(Table 2). We did include this patient based on
the pathogenic molecular findings of a splice
site mutation that would truncate CHD7; inter-
estingly, this patient did not have persistent
LSVC. 
The one patient without a pathogenic CHD7
mutation, Patient 4, also had normal microar-
ray and 22q11 FISH testing. LSVC was present
and this patient had typical features of
CHARGE including choanal stenosis, growth
delay (length 0.2% at 6 months of life), striking
ear anomalies (right microtia, left anotia,
absent left tympanic membrane, malrotated
left middle ear ossicles fused to the inferior
wall, dysmorphic stapes, hypoplastic oval win-
dow, right incus fused to lateral wall, superior
semicircular canal partially absent, dysmor-
phic, and large undeveloped horizontal semi-
circular canal), severe to profound hearing
loss bilaterally (conductive hearing loss ipsi-
lateral to anotia), cranial nerve anomalies
(absent right facial nerve and tortuous left
facial nerve) with broad forehead and square
facies. Cardiac findings are listed in Table 3.
No colobomas were seen on ophthalmologic
evaluation. This patient also had additional
rare and severe craniofacial findings including
absent left internal carotid artery and absent
left parotid gland, some of which have been
previously described in the case report litera-
ture in association with CHARGE syndrome.17
This patient met Blake and Verloes criteria for
a clinical diagnosis of typical CHARGE syn-
drome, and may be one of the <10% of patients
meeting this standard that do not have muta-
tions of CHD7.7
All patients had unique phenotypic features.
Molecular findings of all patients showed a
preponderance of splice site and premature
stop codon mutations. 
Discussion and Conclusions
Early diagnosis of genetic syndromes is
important for optimal patient care in the CICU
setting, as knowledge of a unifying diagnosis
informs medical decision making, perioperative
care, identification and management of comor-
bidities, improved attention to feeding difficulty
in patients with increased risk of dysphagia, and
postoperative rehabilitative therapy. 
Establishing a diagnosis of CHARGE syn-
drome in a newborn may be delayed by failure
to meet full clinical diagnostic schema in
infancy, delay in molecular testing, and/or fea-
tures that overlap with more common or well-
known genetic syndromes such as 22q11.2
deletion syndrome. Usually in newborn care,
unless suggested by genetics consult, teams
will not routinely order an ophthalmology con-
sult that may detect a retinal coloboma, facial
bone imaging for unilateral choanal atresia, or
audiology testing that might lead to the diag-
nosis of CHARGE syndrome in a newborn with
conotruncal defects. Identification of addition-
al features, which increase suspicion for
CHARGE syndrome and assist in delineating it
from other common syndromes, would assist
in identifying patients who should have CHD7
sequencing, and in appropriate diagnosis of
patients who may be too young to meet the
clinical criteria of CHARGE syndrome. 
This study identifies LSVC as a possible new
phenotypic association for CHARGE syndrome.
Echocardiograms are routinely performed to
                             Brief Report
Table 1. Comparison of clinical criteria for CHARGE syndrome.
Author    Major criteria                                                       Minor criteria                                                                       Clinical diagnosis
Blake3         1. Coloboma, microphthalmia                                               1. Cardiovascular malformations                                                               Typical CHARGE:
                    2. Choanal atresia or stenosis                                              2. Tracheo-esophageal defects                                                                  4 major or
                    3. Characteristic external ear anomaly,                                                                                                                                                        3 major + 3 minor
                    middle/inner ear malformations, mixed deafness          3. Genital hypoplasia or delayed pubertal development                      
                    4. Cranial nerve dysfunction                                                 4. Cleft lip and/or palate                                                                              
                                                                                                                       5. Developmental delay                                                                                
                                                                                                                       6. Growth retardation                                                                                   
                                                                                                                       7. Characteristic face                                                                                   
Verloes4     1. Ocular coloboma                                                                 1. Heart or esophageal malformation                                                      Typical CHARGE
                    2. Choanal atresia                                                                    2. Malformation of the middle or external ear                                      3 major or
                    3. Hypoplastic semicircular canals                                      3. Rhombencephalic dysfunction including                                            2 major + 2 minor
                                                                                                                         sensorineural deafness                                                                               Partial CHARGE
                                                                                                                       4. Hypothalamo-hypophyseal dysfunction                                               2 major + 1 minor
                                                                                                                         (gonadotropin or growth hormone deficiency)                                    Atypical CHARGE
                                                                                                                       5. Mental retardation                                                                                   2 major + 0 minor or
                                                                                                                                                                                                                                                1 major + 1 minor
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screen for cardiac defects in patients suspect-
ed of having CHARGE syndrome, so this infor-
mation would be available and accessible to
geneticists and cardiologists. In our small ret-
rospective review we have found a high propor-
tion of patients with CHARGE syndrome who
had persistent LSVC, suggesting that this
anomaly in the presence of another cardinal
feature of CHARGE syndrome might trigger
further clinical suspicion for this syndrome.
Defining the frequency of LSVC in CHARGE is
therefore important to this end. Other syn-
dromes on the differential diagnosis for LSVC
include heterotaxy, VACTERL association, ane-
uploidy, and 22q11.2 deletion syndrome.11
Consideration of a potential unifying mech-
anism of the occurrence of LSVC in CHARGE
patients suggests there is some degree of phe-
notypic overlap between CHARGE syndrome
and laterality defects. Specific types of CVMs,
including complex CVM are present in both sit-
uations, but CVMs that are common and large-
ly present in patients without a genetic syn-
drome (such as conotruncal defects) do not
necessarily alter the index of suspicion like
specific CVMs. Our patient population had a
higher than expected prevalence of TGA and
right aortic arch. Most, but not all, patients
with either of these CVMs also had LSVC.
Interestingly, mal-arrangement in addition to
structural defects is present in both condi-
tions, suggesting consideration of arrange-
ment may also facilitate identification of
CHARGE patients. Patient 4 had additional car-
diac features consistent with heterotaxy,
including dextrocardia and total anomalous
pulmonary venous connection. Laterality
defects have been seen in CHD7 knockdown
zebrafish,18 as well as more typical cardiac
anomalies similar to those generally seen in
patients with CHARGE syndrome.19 It may be
that CHD7 plays a role in left-right discrimina-
tion in human cardiac development. 
Limitations of this study include the fact
that all patients were ascertained based on
their CVMs, and we are therefore unable to
assess whether patients with CHARGE syn-
drome may have isolated LSVC. All of the
patients in this study had CVMs, whereas 75%
of patients with CHARGE syndrome have
CVMs,2 reflecting the ascertainment of
patients from a cardiovascular genetics serv-
ice. Additionally, the small sample size of indi-
viduals with CHARGE syndrome in this study
may overestimate this association and not be
generalizable. Arguing against sampling bias,
however, is the high prevalence of CHARGE
syndrome in an LSVC population study11 and
increased SVC anomalies in an epidemiologic
study of patients with CHARGE syndrome.1 A
point may be made that the frequency of this
finding is related to the 10% prevalence of
LSVC in patients with CVMs, however in
reviewing our patient group with 22q11 dele-
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tion with CVMs (n=33) we found three
patients with LSVC (11%), similar to the gen-
eral presence of LSVC in individuals with
CVMs. Larger studies of SVC anomalies in
CHARGE syndrome patients are required to
clarify these limitations.
In summary, we have identified LSVC as a
likely common cardiovascular malformation in
CHARGE, suggesting CHD7 plays a role in
venous development. Other findings sugges-
tive of abnormal development of laterality were
also found in our population (right aortic arch,
dextrocardia, D-TGA). Taken together with the
abnormal laterality development in zebrafish
with CHD7 knockdown, an additional role for
CHD7 in early embryonic left-right patterning
may be considered. CHARGE syndrome should
be considered when LSVC and laterality abnor-
malities are identified. 
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Table 3. Cardiovascular malformation and left superior vena cava status.
Patient    CVM groups            CVM lesions                                                            LSVC
1                   Conotruncal                   Double outlet right ventricle
                    RVOTO                            Pulmonary valve stenosis
                                                              Right aortic arch                                                                               -
2                   Conotruncal                   Interrupted aortic arch, type B
                    Septal                              Ventricular septal defect
                                                              Aberrant right subclavian artery                                                   -
3                   Septal                              Atrial septal defect
                                                              Patent ductus arteriosus                                                                -
4                   Conotruncal                   Dextrocardia
                    APVR                                D-Transposition of the great arteries
                    RVOTO                            Total anomalous pulmonary venous return
                                                              Tricuspid stenosis                                                                           +
5                   Conotruncal                   D-Transposition of the great arteries
                    RVOTO                            Pulmonary valve stenosis                                                              +
6                   Septal                              Ventricular septal defect
                                                              Patent ductus arteriosus                                                                -
7                   Conotruncal                   Double outlet right ventricle
                                                              Mitral atresia
                                                              Right aortic arch                                                                              +
8                   Conotruncal                   D-Transposition of the great arteries
                                                              Right aortic arch
                                                              Aberrant left subclavian artery                                                     +
CVM, cardiovascular malformation; LSVC, left superior vena cava; RVOTO, right ventricular outflow tract obstruction; APVR, right aortic arch,
dextrocardia.
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